Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

AEs will be graded using National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5. Counts of all AEs by grade will be provided by treatment arm.

The EPIC-26 sexual domain will be assessed as an exploratory endpoint but following the analysis plan specified for the EPIC-26 urinary and bowel domains.

Median failure-free survival time comparing the curves.

Median survival time comparing the curves.

Median MFS time comparing the curves.

Proportion of patients with a decline, as measured by the urinary incontinence domain of the Expanded Prostate Cancer Index Composite (EPIC-26).

Proportion of patients with a decline, as measured by the urinary irritative/obstructive domain of the Expanded Prostate Cancer Index Composite (EPIC-26).

Proportion of patients with a decline, as measured by the bowel domain of the Expanded Prostate Cancer Index Composite (EPIC-26).

Proportion of patients with a decline, as measured by the Patient Reported Outcomes Measurement Information System-Fatigue.

Measured by the Functional Assessment of Chronic Illness Therapy-COST.

Will estimate the primary outcome treatment effect and the corresponding 95% confidence intervals (CIs) by sex.

Will estimate the primary outcome treatment effect and the corresponding 95% CIs by race.

Will estimate the primary outcome treatment effect and the corresponding 95% CIs by ethnicity.